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Longitudinal changes in exercise capacity 
among adult cystic fibrosis patients
Abstract
Introduction: Longitudinal data regarding changes in exercise capacity among adult cystic fibrosis (CF) patients are current-
ly scarce. The aim of this brief report was to assess changes in exercise capacity among adult CF patients with stable and 
mild-to-moderate disease eight years after their initial evaluation.
Material and methods: Maximum cardiopulmonary exercise testing (CPET) was utilized. Other assessments included Doppler 
echocardiography, the 6-minute walking test, spirometry, and lung volume evaluation. 
Results: Eleven (6 male, 5 female) patients completed both evaluations (initial and after eight years). During follow-up, indices of 
ventilatory impairment (such as ventilatory reserve; p=0.019, and ventilatory equivalent for carbon dioxide; p = 0.047) deterio-
rated significantly following a decline in respiratory function measurements. Peak oxygen uptake (VO2), both as an absolute (26.6 
± 8.46 vs 23.89 ± 6.16 mL/kg/min; p = 0.098) and as a % of predicted value (71.21 ± 16.54 vs 70.60 ± 15.45; p = 0.872), 
did not deteriorate. This is also true for oxygen pulse (p = 0.743), left heart ejection fraction (p = 0.574), and pulmonary artery 
systolic pressure (p = 0.441). However, the anaerobic threshold, both as an absolute (p = 0.009) and as a % of predicted value 
(p = 0.047), was significantly lower during follow-up. 
Conclusion: In adult CF patients with stable, mild-to-moderate disease, a peak VO2 may be preserved for several years. However, 
even in these patients, deconditioning is present.
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Introduction
Exercise impairment in patients with cystic 
fibrosis (CF) is well established and has been 
attributed to a variety of pulmonary and non-pul-
monary factors [1]. Although several tests have 
been previously adopted to assess exercise capac-
ity in this patient population, cardiopulmonary 
exercise testing (CPET) offers an integrative as-
sessment of the pulmonary, cardiovascular, and 
skeletal muscle system responses during exercise 
[2]. Moreover, peak oxygen uptake (VO2), which 
is assessed during maximum CPET, is related to 
quality of life and is a strong predictor of hospi-
talization and mortality in adult CF patients [3–6]. 
As CF is a progressive disease, exercise capac-
ity may deteriorate in time following pulmonary 
and extra-pulmonary manifestations. However, 
data on longitudinal changes of peak VO2 and 
other CPET variables in adult CF patients are 
currently scarce. In the few available studies, 
changes in CPET variables were followed up for 
12–18 months [7, 8], a period probably not long 
enough for disease deterioration to manifest. 
Moreover, all available studies were conducted in 
children or adolescents [7, 8]. However, several 
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different, non-specific factors may complicate 
the pathophysiology of exercise limitation of the 
adolescent versus adult CF patient population 
(e.g. age of first CF presentation, effects of aging 
on cardiovascular function, different CPET ap-
proach, cautious caregiver that limits exercise 
participation, etc.) [3, 9]. Therefore, findings 
cannot be generalized. Under this scope, we 
conducted a pilot longitudinal study to assess the 
changes in peak VO2, anaerobic threshold (AT), 
and other CPET variables eight years after initial 
evaluation in a population of adult CF patients 
with mild-to-moderate disease.
Materials and methods
Between September 2010 and June 2011, 
17 adult CF patients prospectively underwent 
maximum CPET and Doppler echocardiogram; 
the details are published elsewhere [1]. From this 
initial population, all surviving adult CF patients 
who had not undergone lung transplantation, 
were not lost to follow-up, and gave informed 
consent for participation were re-assessed be-
tween October 2018 and September 2019. All 
participating patients were regularly attending 
the adult CF unit of a major chest hospital in 
Greece, were life-long non-smokers, and were 
in a stable condition. In case of an exacerbation 
during the baseline assessment, the patient was 
properly treated and re-entered the protocol after 
at least 3 months of disease stabilization. Patients 
who received long-term oxygen treatment or pre-
sented with any contraindications for CPET were 
excluded. Ethical approval for the study protocol 
was received from the G Papanikolaou Hospital 
Scientific Committee.
The study protocol consisted of two visits 
conducted within a frame of one week. During the 
first visit, all patients underwent spirometry, lung 
volume measurement, and a 6-minute walking 
distance (6MWD) test. During the second visit, all 
patients underwent a transthoracic echocardio-
graphic study (Philips medical system, Andover, 
MA, USA). Pulmonary artery systolic pressure 
(PASP), ejection fraction, and left and right heart 
dimensions were obtained by previously recom-
mended techniques (10,11). Following this, all 
patients conducted a maximum CPET on a cycle 
ergometer. The exercise protocol required 2 min-
utes of unloaded pedaling with a ramp increase of 
work rate by 10-15 watts/minute until exhaustion 
followed by 3 minutes of recovery. The Borg dys-
pnea scale and the Borg Rate of Perceived exertion 
(RPE) were also recorded. Statistical analysis was 
conducted utilizing the SPSS, version 20 for Win-
dows XP. The Shapiro-Wilk test was applied to as-
sess whether the distribution of data was normal 
or not. The paired samples t-test or the Wilcoxon 
rank test were utilized for group comparisons 
based on the normality of distribution of values 
with a level of p < 0.05 considered significant.
Results
Eleven patients (6 male, 5 female) who suf-
fered from mild-to-moderate disease completed 
both assessments (initial, and after eight years). 
Seven patients had a Medical Research Council 
(MRC) dyspnea scale rating of 0–1, 3 patients had 
a rating of 2, and only one patient had a rating 
of 3. Moreover, the number of annual CF exac-
erbations which required hospitalization and 
intravenous antibiotic treatment was also limited 
in most of the cases. Specifically, 9 patients had 
0-1 such exacerbations annually and only two 
had ≥ 3. Compared to the initial assessment, re-
spiratory function, evaluated by forced expiratory 
volume in 1 second (FEV1), and total lung capacity 
(TLC) deteriorated. However, forced vital capac-
ity (FVC) was similar during follow up (Table 1). 
The body mass index (BMI) of patients did not 
change longitudinally, while left heart function 
(as assessed by ejection fraction, p = 0.574) and 
systolic pulmonary artery pressure (p = 0.441) 
was also similar during follow-up.
Changes in the exercise capacity of these pa-
tients are also presented in Table 1. The follow-up 
6MWD was significantly lower when compared 
with the initial one (605 ± 58.5 vs 513 ± 73.45; 
p = 0.001) and patients presented with more 
severe desaturation during the test. Maximum 
exercise capacity, as assessed by absolute peak 
VO2 (26.6 ± 8.46 vs 23.89 ± 6.16; p = 0.098), % 
of predicted peak VO2 (71.21 ± 16.54 vs 70.60 ± 
15.45; p = 0.872), and % of predicted peak work 
rate (WR) (65.2 ± 13.63 vs 63.7 ± 15.09; p = 
0.559) was below normal, but similar between 
the two evaluations. On the contrary, AT (both as 
an absolute and as a % of predicted values) was 
significantly lower during the second evaluation 
(p = 0.009 and p = 0.048, correspondingly). As 
for the rest of CPET parameters, the ventilatory 
equivalent for carbon dioxide at AT (VE/VCO2@
AT) was higher (p = 0.047) and the ventilatory 
reserve by the end of the exercise was lower (p 
= 0.019) during follow-up, although it should be 
noted that peak minute ventilation (VE) did not 
differ between the two time periods. The oxygen 
pulse (peak VO2/peak heart rate), Borg dyspnea, 
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and Borg RPE scores were also similar during the 
two evaluations.
Discussion
Pulmonary, cardiac, metabolic, or peripher-
al muscle disorders may all negatively impact 
peak VO2 [2]. Previous literature indicated that 
a peak VO2 may be largely preserved in children 
and adolescents with mild CF [8, 9, 12]. In our 
study, VE/VCO2 increased (indicating an increase 
in dead space ventilation) as was expected, and 
breathing reserve decreased during follow up. 
These abnormalities are frequently present among 
patients with CF even when peak VO2 is preserved 
[7, 9] because they follow the pattern of typical 
respiratory function decline. Respiratory limita-
tion is an important pathophysiological factor 
of dyspnea and exercise limitation in chronic 
respiratory diseases [13]. Nevertheless, correla-
tions between exercise outcome parameters and 
FEV1 and/or FVC are often weak or absent in CF 
patients [3, 8], which suggests that respiratory 
restriction might not always be the major cause 
of exercise limitation. Moreover, cardiac index 
is a strong predictor of exercise outcome during 
CPET in CF patients [14]. The fact that oxygen 
pulse (an index of cardiac output) along with 
echocardiographic indices of left heart function 
and pulmonary circulation did not deteriorate in 
our study may partially explain why peak VO2 did 
not further decrease after eight years.
Table 1. Longitudinal changes of anthropometrics, lung function, echocardiographic parameters and exercise capacity 
variables among adult CF patients
Parameters Initial evaluation Follow-up evaluation p
Age [years] 27.2 (4.15) 34.63 (3.98) <0.001
Body mass index [kg/m2] 22.2 (2.65) 23.1 (3.65) 0.231
Forced expiratory volume in 1 second (FEV1)







Forced vital capacity (FVC)







FEV1/FVC 77.42 (18.87) 62.33 (13) 0.005
Total lung capacity [%predicted] 81.69 (14.71) 69.83 (14.25) 0.005
Ejection fraction [%] 66.6 (4.3) 66.4 (3.9) 0.574
Pulmonary artery systolic pressure [mm Hg] 24.18 (6.57) 24.72 (5.87) 0.441
6 minute walking distance [m] 605 (58.5) 513 (73.45) 0.001
SpO2 rest* [%] 95 (4)* 95 (5)* 0.726**
SpO2 nadir* (during 6 minute walking test) [%] 94 (15)* 92 (15)* 0.005**
Peak oxygen uptake 
   mL/kg/min








   mL/kg/min








   watts







Borg dyspnea* (at peak VO2) 3 (6)* 5 (8)* 0.347**
Borg RPE* (at peakVO2) 4 (6)* 5 (5)* 0.354**
Peak VO2/peak heart rate [% predicted] 83.94 (15.61) 82.13 (13.86) 0.743
VE/VCO2@AT 31.2 (3.73) 33.6 (3.78) 0.047
Peak minute ventilation [lit] 60.89 (23.61) 63.19 (23.1) 0.483
Ventilatory reserve (MVV-peak VE) [lit] 40 (30.98) 16.7 (17.8) 0.019
All data are presented as mean (SD), unless otherwise indicated. *Median (range). **Wilcoxon rank test was utilised for group comparisons.
MVV — maximum voluntary ventilation; RPE — rate of perceived excursion; SpO2 — pulse oxymeter oxygen saturation; VE/VCO2@AT — ventilatory equivalent for 
carbon dioxide at anaerobic threshold; VE — minute ventilation; VO2 — oxygen uptake
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Contrary to peak VO2, both the 6MWD and AT 
declined with time. The 6MWD test is considered 
a submaximal exercise test [15] so its decline 
cannot accurately reflect the maximal exercise 
capacity of the patients, but it associates well 
with most activities of daily living [15]. Moreover, 
the reduced AT, without signs of cardiovascular 
involvement, probably reflects the physical inac-
tivity and deconditioning that has been frequently 
observed among CF patients [16, 17]. Exertional 
dyspnea, or the fear of it, combined with malnutri-
tion, muscle cachexia, and disease exacerbations 
are only some of the causes [18].
Conclusion
In conclusion, in a population of CF patients 
with mild-to-moderate disease, the maximum 
exercise capacity did not decline further over 
8 years. This is contrary to AT and 6MWD, which 
did decline. To our knowledge, no other study has 
yet provided data of such a long-term follow-up 
regarding CPET variables in this patient popula-
tion. This study’s findings are somewhat limited 
by the small number of participants and by the 
fact that only patients with mild-to-moderate 
disease, which remained relatively stable over 
the years, were analyzed. However, our study 
does make the point that, even in CF patients 
with long-term preserved peak VO2, physical de-
conditioning may be present. As CF patients with 
higher aerobic fitness present with better quality 
of life and higher survival [17], one could hypoth-
esize that comprehensive exercise programs with 
continuous training in the long-term might be an 
important adjunct to regular treatment, even for 
CF patients with milder disease. 
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